- 1 Title: Magnetofluidic platform for rapid multiplexed screening of SARS-CoV-2 variants and respiratory
- 2 pathogens
- 3 Authors: Alexander Y. Trick^{1*}, Fan-En Chen^{1*}, Liben Chen^{2**}, Pei-Wei Lee², Alexander C. Hasnain¹, Heba
- 4 H. Mostafa³, Karen C. Carroll³, Tza-Huei Wang^{1,2,4**}
- 5 *Co-first author
- 6 **Co-corresponding author
- 7 ¹Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 21218, USA
- 8 ²Department of Mechanical Engineering, Johns Hopkins University, Baltimore, MD 21218, USA
- 9 ³Division of Medical Microbiology, Department of Pathology, Johns Hopkins University School of
- 10 Medicine, Baltimore, MD 21205, USA
- ⁴Institute for NanoBiotechnology, Johns Hopkins University, Baltimore, MD 21218, USA

12 Abstract

13 The rise of highly transmissible SARS-CoV-2 variants brings new challenges and concerns with 14 vaccine efficacy, diagnostic sensitivity, and public health responses in the fight to end the pandemic. 15 Widespread detection of variant strains will be critical to inform policy decisions to mitigate further 16 spread, and post-pandemic multiplexed screening of respiratory viruses will be necessary to properly 17 manage patients presenting with similar respiratory symptoms. In this work, we have developed a 18 portable, magnetofluidic cartridge platform for automated PCR testing in <30 min. Cartridges were 19 designed for multiplexed detection of SARS-CoV-2 with either distinctive variant mutations or with 20 Influenza A and B. The platform demonstrated a limit of detection down to 2 copies/µL SARS-CoV-2 RNA 21 with successful identification of B.1.1.7 and B.1.351 variants. The multiplexed SARS-CoV-2/Flu assay was 22 validated using archived clinical nasopharyngeal swab eluates (n = 116) with an overall 23 sensitivity/specificity of 98.1%/95.2%, 85.7%/100%, 100%/98.2%, respectively, for SARS-CoV-2, Influenza 24 A, and Influenza B. Further testing with saliva (n = 14) demonstrated successful detection of all SARS-CoV-25 2 positive samples with no false-positives.

26 Introduction

27 While the development and distribution of vaccines brings hope for a return to normalcy, 28 extensive diagnostic testing remains critical to curbing the spread of the SARS-CoV-2 virus¹⁻³. Even with 29 vaccines, the rise of highly transmissible virus variants that have dominated recent coronavirus disease 30 2019 (COVID-19) outbreaks raises concerns about mutations leading to potential escape from vaccine protection⁴⁻⁶. Insufficient screening and surveillance has left public health officials with large gaps in 31 32 knowledge of the extent and impact of these variants⁷. Furthermore, demand for testing will continue 33 after the pandemic wanes, as it is predicted that COVID-19 will maintain circulation alongside other 34 seasonal or endemic respiratory viruses presenting with similar symptoms, such as influenza⁸. Multiplexed 35 diagnostic screening for detection of SARS-CoV-2 variants and other respiratory pathogens must be made 36 widely accessible to provide targeted treatments to patients and notify policy makers if more stringent 37 measures are needed to control transmission.

38 Broad identification of virus variants and infectious pathogens can be achieved with genomic 39 sequencing, but the necessary equipment and data processing required to conduct sequencing 40 procedures is currently prohibitively expensive and complex for universal adoption⁹. Instead of 41 sequencing, nucleic acid amplification tests (NAATs) typically used for infectious disease diagnosis may be 42 readily modified to detect characteristic sequences of variants¹⁰. Although relatively easy to implement compared to sequencing, the increase in demand for NAATs during the SARS-CoV-2 pandemic has 43 44 revealed severe deficiencies in public access to infectious disease diagnostics and aggravated existing 45 shortages in testing capacity, supplies, and laboratory personnel¹¹.

46 The gold standard NAATs for detection of SARS-CoV-2 RNA and other respiratory viruses use reverse-transcription polymerase chain reaction (RT-PCR)¹². These tests provide the greatest sensitivity 47 and specificity, but often require transport to high complexity laboratories in centralized test facilities 48 49 which can lead to large backlogs with turnaround times of days or weeks^{11,13}. Test results should ideally 50 be delivered on-site at the testing location to facilitate recording of accurate surveillance data and to 51 enable immediate notification of the test results to the patient for initiating guarantine or linkage to care. 52 Currently available rapid NAAT platforms use expensive instruments and test cartridges making rapid 53 screening for a large population with these systems unrealistic. Because of the long turnaround times and 54 high cost per test of current NAAT platforms, many strategies for large scale testing opt for cheaper 55 antigen tests¹⁴. Compared to PCR, these viral antigen tests have reduced sensitivity, higher rates of falsepositives, and are not easily amenable to multiplexed detection of several genetic targets or 56 pathogens^{15,16}. 57

58 To address the need for affordable and accessible multiplexed NAATs with a fast turnaround time, 59 we developed an imaging-based portable droplet magnetofluidic cartridge platform. Instead of traditional fluidic strategies for sample handling and assay automation, droplet magnetofluidic technologies use the 60 movement of magnetic beads through discrete droplets of reagents to capture, purify, and transfer 61 62 analytes for amplification and/or detection^{17–20}. Recent developments of magnetofluidic cartridges have 63 integrated static assay reagents isolated by immiscible liquid barriers into a low-cost plastic disposable^{21–} ²³. Magnetic transfer of beads along a hydrophobic surface within the cartridges obviates the need for 64 precision fluidic channels and flow controllers that increase the complexity and cost of other automated 65 NAAT platforms^{24,25}. While previous studies using magnetofluidic cartridges were limited to a single 66 67 reaction well per cartridge, this work achieves higher levels of multiplexed detection through a 68 combination of duplexed PCR probe assays and a novel multi-elution aliquoting scheme to distribute 69 nucleic acids.

70 Testing with our platform's disposable cartridges enables sample-to-answer RT-PCR in under 30 71 minutes with detection of up to 4 genetic targets per test. Two different assay cartridges were designed 72 - one for SARS-CoV-2 detection and differentiation of its variants, and another for multiplexed screening 73 of SARS-CoV-2 with Influenza A, and Influenza B. We demonstrated the utility of our cartridge assays by 74 testing with extracted RNA from clinical samples, nasopharyngeal swab eluates, and saliva samples. This 75 platform presents a potent opportunity to expand access to screening SARS-CoV-2 variants and 76 multiplexed respiratory pathogen testing in any setting with minimal training and immediate on-site 77 reporting of results.

78 Results

79 Assay design and workflow

80 To conduct a test, the sample is first mixed with a buffer containing functionalized magnetic beads 81 followed by loading the entire mixture into the sample port of the cartridge. Once sealed with an adhesive 82 tab to prevent leakage of the sample, the cartridge is inserted into a slot in the side of the instrument (Fig. 83 1a, Supplementary Fig. 1). Identifying information for the sample is entered by the user using the 84 instrument's touchscreen interface followed by full automation of nucleic acid extraction, purification, and amplification by RT-PCR. The instrument conducts real-time analysis of fluorescent signals with fully 85 86 interpreted results displayed on the screen in under 30 minutes. Each instrument has a compact footprint 87 (14.5 cm x 21.6 cm x 14.5 cm) and built-in wireless connectivity for potential integration with laboratory 88 information systems.

89 We designed two different cartridge assays (Fig. 1b-c) for either detection of SARS-CoV-2 variants 90 of concern, or multiplexed diagnosis of SARS-CoV-2 with Influenza A and B. Both cartridges employ two 91 duplexed PCR assays in separate wells containing hydrolysis probes labelled with FAM or Cy5/TYE 92 fluorophores for a total of 4 target sequences per cartridge. To ensure cartridge reagents are functional 93 and sample processing is fully completed, each cartridge assay detects a synthetic control RNA sequence²⁶ 94 that is pre-mixed in the magnetic bead solution. Detection of SARS-CoV-2 and control RNA are duplexed 95 in the first well in both assays. A conserved nucleocapsid gene (N1) target sequence was adopted for 96 universal detection of SARS-CoV-2²⁷.

97 The cartridge for discrimination of SARS-CoV-2 variants uses the second PCR well for primers and probes designed by Vogel et al.¹⁰ to detect the presence of distinct mutations in the SARS-CoV-2 spike 98 99 (Δ 69-70) and ORF1a (Δ 3675-3677) genes (Fig. 1b). The Δ 69-70 mutation is associated uniquely with the 100 B.1.1.7. variant that has shown high transmissibility.^{4,5} Meanwhile, the ORF1a deletion is found in B.1.1.7, B.1.351, and P.1 variants of concern ¹⁰. Therefore, if both the spike and the ORF1a mutation are present, 101 the virus is classified as B.1.1.7. If the spike mutation is not detected, but the ORF1a mutation is, then the 102 103 virus is classified as potentially B.1.351 or P.1. The PCR probes produce an amplification signal in virus 104 lineages not included within the variants of concern, while signal dropout occurs if the described 105 mutations are present. In the second cartridge designed for multiplexed detection of SARS-CoV-2 with 106 influenza A and B, the second PCR well instead contains a duplex assay containing primers and probes for influenza A and B detection^{28–30} (Fig. 1c). 107



108

109 Fig. 1| Cartridge platform operation. a, Nasal swab eluate or saliva is injected directly into the cartridge with 110 magnetic beads followed by sealing the cartridge and inserting it into the instrument. After magnetofluidic sample 111 preparation and PCR, the instrument reports the assay results on the built-in touchscreen within 30 minutes. b, Each 112 PCR well contains two fluorescent probes in the FAM (green/left) or Cy5 (red/right) spectrum. Cartridges include a 113 duplexed assay for the conserved N1 SARS-CoV-2 sequence and control RNA in the first well. The cartridge designed 114 for detection of SARS-CoV-2 variants includes a duplexed PCR assay in the second well with probes spanning regions 115 that contain deletions found in variants of concern. A lack of amplification in the second well indicates the presence 116 of a mutation and can be used to classify the type of variant present. c, Cartridges designed for multiplexed detection 117 of respiratory pathogens have a duplexed Influenza A and Influenza B PCR assay in the second well.

118 Magnetofluidic cartridge design

119 The thermoplastic cartridge design in this work builds upon previous developments of 120 magnetofluidic cartridges by incorporating greater flexibility in sample input volume, higher multiplexing of biomarkers, and more robust construction for easier handling^{21–23}. Construction of the cartridges uses 121 122 simple lamination techniques of three layers that have been laser-cut and thermoformed (Supplementary 123 Fig. 2). All reagents are pre-loaded into extruded thermoformed wells of the cartridge (Fig. 2a) except for 124 the magnetic beads which are mixed with the sample prior to loading into the cartridge. An immiscible 125 layer of silicone oil provides an evaporation barrier and a fluidic interconnect between reagent wells for 126 transfer of the magnetic beads. By isolating the reagents in thin-walled thermoformed wells, the thermal mass of the reaction can be spatially isolated for targeted, rapid thermocycling leading to faster 127 128 turnaround times than traditional bulky PCR systems.

Once the sample is mixed with the magnetic bead buffer and loaded into the cartridge, the viral particles are lysed with surfactant and heating in the first well to allow for electrostatic binding of viral RNA to the charge-functionalized magnetic beads (Fig. 2b). Transfer of the beads into the second well exchanges the beads into a pH neutral wash buffer for removal of binding salts and any contaminants in the sample which may inhibit PCR (Fig. 2c). Finally, sequential transfer of the beads into the alkaline (pH

8.5) PCR wells allows for neutralization of the bead coating and partial release of captured RNA into each
PCR reaction well (Fig. 2d) for amplification and fluorescence detection. To achieve under 30-minute
turnaround time, sample preparation from lysis to completion of elution takes around 6 minutes, followed
by 5 minutes of reverse transcription, and 50 cycles of PCR thermocycling in under 18 minutes (Fig. 2e).

The cartridge in this work includes several key innovations. A wax plug between the sample well and wash well seals off the oil and downstream reagents to immobilize all downstream fluids during transport and handling, which allows for full range of tilting and shaking the cartridge without reagent leakage. After the user injects the sample into the cartridge port, any excess sample can escape into an overflow reservoir and the port is sealed with an adhesive strip to provide an additional layer of safety from sample contamination and spill of infectious materials.

144 The most critical innovation in this work is the inclusion of an additional PCR well for higher levels 145 of multiplexing coupled with a sequential elution strategy. Sequential elution takes advantage of the 146 incomplete release of captured nucleic acids to aliquot RNA into separate reaction buffers. As the beads 147 are exposed to each new buffer, the captured nucleic acids will be released until an equilibrium between 148 the concentration of analyte on the bead surface and in the reaction buffer is reached. We have 149 demonstrated this technique has potential to expand multiplexing up to at least six separate reactions (Supplementary Fig. 3). This flexibility in multiplexing provides an option to expand future cartridges to 150 151 include additional targets for other SARS-CoV-2 variants or for a larger panel of pathogens.



152

153 Fig. 2| Cartridge design. a, The magnetofluidic cartridge contains preloaded assay reagents for sample purification 154 and PCR. A layer of silicone oil fills the space within the cartridge between reagents, and a wax plug prevents the 155 reagents from leaking during transport such that the first well remains empty for loading the sample. b, The first 156 well is heated to 100°C for 80 seconds (i) to promote viral lysis for RNA capture and to release the wax plug at the 157 base of the sample well to allow passage of magnetic beads. c, Bead transfer into the wash well (ii) promotes removal 158 of salts, proteins, and other sample components that may inhibit PCR. d, Bead transfer into the PCR wells 159 accompanied by heating to 55°C (iii, iv) allows sequential elution of the captured RNA. e, Plot of the temperature of 160 previously described steps for sample preparation followed by one-pot reverse transcription and PCR with real-time 161 2-color fluorescence detection of both reaction wells at each cycle.

162 Instrument design and sample processing

163 The instrument contains all components necessary for transfer of magnetic beads through the 164 cartridge, temperature control to melt wax seals and conduct RT-PCR, and optics for fluorescence excitation and detection (Fig. 3a-b). Instead of complex fluidics, valves, and pressure controllers typically 165 166 found in microfluidic instrumentation, the components here include primarily low-cost hobby servo 167 motors and off-the-shelf LED and CMOS camera parts (Supplementary Table 1). Once the cartridge is 168 inserted into the instrument, it is detected with the CMOS camera, which uses the fluorescent outline of 169 the PCR wells to determine if the cartridge is properly positioned. The fluorescence detection uses dual 170 bandpass filters over the CMOS camera for emission, and over a 2-color LED for excitation to permit multi-

171 color detection without moving parts by alternating blue and red LED illumination for FAM and Cy5/TYE 172 fluorophores, respectively. Three servo motors automate application of the heat blocks to the cartridge 173 and magnetic bead transfer (Supplementary Fig. 4). If the cartridge has been inserted fully, then the first 174 servo motor involved rotates a shaft to mount both the sample heat block and PCR heat block onto the 175 cartridge. With the heat blocks mounted, a power resistor heats the sample heat block to 100°C for 80 176 seconds to both promote viral lysis and melt the wax plug which then floats toward the top of the cartridge 177 leaving a clear passage for transfer of the magnetic particles (Fig. 3c).

178 A second servo motor swivels two opposing neodymium permanent magnets to the bottom or 179 top of the cartridge to pellet beads into reagent wells or extract them into the oil layer. The third servo 180 motor translates this magnet arm along the length of the cartridge for transfer of the beads between wells 181 through the oil (Supplementary Video 1). This magnetic transfer paradigm allows the beads to be transferred anywhere along the long axis of the cartridge for compatibility with cartridge designs 182 183 constructed with varying well number, dimensions, and positioning. With the wax melted, the beads are collected out of the sample well to the top of the cartridge and transferred into the wash buffer well to 184 185 remove contaminants that might inhibit function of the downstream PCR assays (Fig. 3d). After alternate 186 application of the top and bottom magnets for three repeated exchanges of the beads into and out of the 187 wash buffer, the beads are finally transferred sequentially into the PCR wells (Fig. 3e). Each well receives 188 the beads for 1 minute while the PCR buffers are heated to 55°C to facilitate release of the capture RNA 189 and initiate reverse transcription. This multi-elution strategy permits some control over the release of 190 RNA with higher elution temperature providing a higher fraction of RNA recovered in each well (Fig. 3f).

Immediately after elution, generation of cDNA and amplification is carried out with reverse 191 192 transcription and PCR thermocycling. Temperature in both wells is simultaneously controlled by the PCR 193 heat block with 2 second holds at 100°C for cDNA denaturation followed by 2 seconds at 55°C for 194 annealing and extension. Miniaturization of the PCR heat block's thermal mass and the use of copper's 195 high thermal conductivity (~400 W/m-K) enables rapid changes in temperature powered by a heatsinked 196 thermoelectric element (Supplementary Fig. 5). The optimized heat block has temperature ramp rates ranging between 6 to 10°C/s for both heating and cooling. When combined with time required for 197 198 denaturation and annealing holds, controlled approaches to targeted temperatures, and image capture 199 for fluorescence detection, this rapid thermocycling leads to completion of 50 cycles of PCR in less than 200 18 minutes.



201

202 Fig. 3 | Instrumentation for automated sample preparation and multi-elution. a, Fluorescence detection optics and 203 heat blocks assembly. b, Servo motor arrangement for (1) mounting heat blocks onto the cartridge, (2) swiveling 204 magnets to the top and bottom of the cartridge for bead extraction and introduction into wells, and (3) translating 205 the magnet arm along the cartridge for bead transfer between wells. c, Rotation of the heat blocks mounts them 206 onto the cartridge followed by sample well heating to promote sample lysis and melt the wax seal. d, Translation of 207 the top magnet from the sample well to the wash well followed by swiveling the magnet arm to swap the bottom 208 magnet into close proximity with the cartridge pulls the beads into the wash buffer. e, Sequential transfer of beads 209 into the first PCR well and then the second elutes captured RNA into both reactions. f, The first elution releases more 210 RNA than the second elution with tunable release of the overall fraction of RNA by changing temperature of the 211 buffer during elution. Both elution steps were run in triplicate at each temperature condition and shown here fit 212 with a linear regression with 95% confidence interval bands.

213 Assay cartridge analytical sensitivity and specificity

Throughout thermocycling, the CMOS camera takes a picture of the PCR wells for each fluorescence channel at the end of each cycle's annealing step (Fig. 4a). The pixel intensity for each well is isolated and averaged to generate a real-time fluorescence curve (Fig. 4b), from which the cycle threshold (Ct) is determined with an automated thresholding algorithm (Supplementary Fig. 6). Detection of amplification and Ct calculation is conducted at the end of each cycle during the test for live reporting of results to the user. For high viral load samples (Ct <20), detection of targets may be reported within 18 minutes from insertion of the cartridge into the instrument.

221 Using the respiratory panel cartridge design, 50 µL samples containing serial dilutions of 222 inactivated SARS-CoV-2, influenza A, or influenza B viral particles were loaded into cartridges with 223 magnetic bead solutions. Each dilution was run in triplicate. Both SARS-CoV-2 and Influenza A were 224 detectable in all replicates down to 2 copies/µL of sample (Figs. 4c-f), while Influenza B was detected down 225 to 24 copies/µL of sample (Figs. 4g, h). We also demonstrated detection of SARS-CoV-2 spiked into saliva with a limit of detection of 12.5 copies/ μ L (Supplementary Fig. 7). To assess the specificity of the assay, 226 the cartridges were run using a panel of 14 viral and bacterial pathogens (Supplementary Table 2). No 227 228 cross-reactive false-positive amplification was detected for any pathogens in the specificity testing panel.



229

Fig 4 Cartridge PCR fluorescence curves and analytical sensitivity. a, Fluorescence images of PCR wells in the FAM and Cy5 channels taken at the annealing step for each cycle with corresponding real-time fluorescence curves plotted in (b). Solid lines and dotted lines in (b) correspond to the top and bottom wells respectively. Standard curves

with Ct values and corresponding average of triplicate fluorescence curves with standard error are shown for SARS-

234 CoV-2 (**c-d**), influenza A (**e-f**), and influenza B (**g-h**).

235 Clinical sample validation

236 Using the cartridge for detection of SARS-CoV-2 variants we evaluated clinical samples from Johns 237 Hopkins Hospital (JHH) as well as extracted RNA from B.1.1.7 and B.1.351 variants. All samples were previously classified by sequencing using the ARTIC protocol³¹ into three categories as either (1) B.1.1.7, 238 239 (2) B.1.351/P.1, or (3) Other, indicating sample did not possess the characteristic mutations of current 240 variants of concern (Table 1). All JHH samples (n = 4) amplified N1, ORF1a, and spike targets indicating they were not one of the variants of concern. Samples previously classified as B.1.1.7 variants (n = 4) by 241 242 sequencing produced fluorescent amplification signals for N1 on cartridge, but no amplification of either 243 the ORF1a or the spike targets and were accordingly classified properly. The samples characterized as 244 B.1.351 (n = 3) by sequencing produced signals for N1 and spike, but did not amplify the ORF1a target 245 resulting in proper classification as B.1.351 or P.1.

Sample	N1-Ct	ORF1a-Ct	Spike-Ct	Classification
JHH #1	30.39	32.57	32.64	Other
JHH #2	30.78	34.44	33.85	Other
JHH #3	28.73	38.10	27.49	Other
JHH #4	28.33	45.57	27.54	Other
B.1.1.7 #1	26.03	Not detected	Not detected	B.1.1.7
B.1.1.7 #2	32.03	Not detected	Not detected	B.1.1.7
B.1.1.7 #3	34.38	Not detected	Not detected	B.1.1.7
B.1.1.7 #4	30.13	Not detected	Not detected	B.1.1.7
B.1.351 #1	33.03	Not detected	37.59	B.1.351 or P.1
B.1.351 #2	28.29	Not detected	37.59	B.1.351 or P.1
B.1.351 #3	32.78	Not detected	31.49	B.1.351 or P.1

246 Table 1. Detection of SARS-CoV-2 Variants

247

248 To assess performance of the respiratory pathogen panel cartridges, we tested clinical swab 249 eluates (n = 116) and passive drool saliva (n = 14). As a comparator assay, samples were first assessed with 250 a benchtop assay adapted from the CDC recommended protocol (Supplementary Fig. 8)³². Of the swab samples, 54 were positive for SARS-CoV-2, 14 were Flu A positive, and 4 were Flu B positive using cutoff 251 252 Ct values at 45, 49, and 47 respectively. Saliva samples contained 7 SARS-CoV-2 positives all of which were 253 correctly classified with the cartridge assay. Only one of the SARS-CoV-2 samples went undetected in 254 cartridge, which was a swab eluate with a relatively late Ct (37.2) by the benchtop comparator assay 255 indicating a low viral titer. Of the negative SARS-CoV-2 swab samples, three false-positives were detected 256 using cartridges, all with late Cts (> 39) indicative of possible low-level contamination from handling other 257 positive samples. Sensitivity and specificity for detection of SARS-CoV-2 from swabs was 96.3% (95% 258 confidence interval: 90.7-100%) and 95.2% (88.7-100%), respectively.

The cartridge Flu A assay missed detection of 2 out of the 14 positives which both had the lowest viral load of the Flu A samples (Ct >35), but yielded full concordance with negative samples, resulting in a sensitivity and specificity of 85.7 (64.3-100%) and 100%, respectively. For Flu B, all 4 positives were detected in cartridge with just one false-positive resulting in a specificity of 98.2% (95.5-100%). We have

excluded 5 negative samples and 4 SARS-CoV-2 positive samples that produced invalid cartridge results
 with no amplification of the control or any other targets (Supplementary Table 3). These invalid results
 may be a consequence of samples with relatively high levels of inhibitory compounds.

266



267

Fig. 5 | Clinical sample validation. a-c, PCR cycle threshold (Ct) values for swabs (*n* = 116) and saliva samples (*n* = 14) run in the multiplexed respiratory panel cartridges. Each point represents one sample with positive (+) and negative (-) classification determined by the benchtop comparator assay and denoted by color. All reactions with undetectable amplification are plotted with a Ct of 50 or higher. Cutoff Ct values for each assay are indicated with a horizontal dashed line. d-f, Corresponding receiver operator curves for the SARS-CoV-2, Flu A, and Flu B cartridge assays. Area under the curve (AUC) is indicated with 95% confidence interval.

274 Discussion

There is an urgent need for affordable and mass-produced testing options that can provide rapid, multiplexed results for identification of variants and to allow future screening of SARS-CoV-2 with other diseases that produce similar respiratory symptoms. Compared to the intricate multi-component designs of current commercially available cartridges, our simple thermoplastic cartridges demonstrate great potential as a highly cost-effective and scalable solution, which is amenable to industrial manufacturing techniques such as roll-to-roll molding, lamination, and die-cutting.

281 Numerous *in vitro* diagnostic companies and researchers propose the use of isothermal NATs as PCR 282 alternatives to leverage the sensitivity of RNA-based detection while reducing cost with simplified 283 instrumentation or "instrumentation-free" testing^{33,34}. These tests have been developed using isothermal

techniques such as loop-mediated isothermal amplification (LAMP)^{35,36}, recombinase polymerase amplification (RPA)³⁷, or CRISPR-Cas based detection of viral RNA³⁸. However, the need for manual processes to purify and concentrate sample RNA to achieve high sensitivity assays is often overlooked. Our magnetofluidic cartridges completely automate nucleic acid purification and concentration and minimize user intervention for reading results.

Our platform enables detection of multiple SARS-CoV-2 variants or other respiratory pathogens, while traditional rapid lateral-flow antigen tests and isothermal tests typically lack the ability to multiplex detection of several pathogens without either setting up multiple separate tests or requiring further postprocessing steps for detection^{39–41}. Post-processing of amplified products for readout of results adds an additional manual step which reduces the likelihood of adoption where a high-volume of tests requires minimal hands-on time. Furthermore, any handling of amplified product raises risks of contamination which would compromise test specificity.

Most low-cost rapid tests have minimal connectivity, making streamlined acquisition of patient results for surveillance difficult and can result in under-reporting of cases⁴². For widespread adoption, on-site multiplexed diagnostic methods need a user workflow as simple, fast, and affordable as lateral flow strips while maintaining connectivity for connecting to clinical databases for improving surveillance. This platform meets these needs in a compact user-friendly format that is compatible with various sample types including PBS, universal transport media, and saliva.

302 For realistic deployment, there are a few limitations to the current platform that must be addressed. 303 In particular, the current cartridges are not shelf-stable for prolonged storage at room-temperature and 304 are refrigerated or frozen prior to use. We are currently investigating techniques for built-in storage of 305 dry reagents to allow stability at ambient conditions. To include testing for additional variants or respiratory pathogens, the cartridge would need to be expanded from the current 2-well design with 306 307 additional PCR wells for higher multiplexing. Given the limited clinical sample volume available in this 308 study, the assay design used a maximum 50 µL input per sample, though further improvement to 309 sensitivity to prevent false-negatives may be achieved by adapting the cartridge and binding buffer to be 310 compatible with larger volumes of sample.

311 Methods

312 RT-PCR assay composition

313 A 7.5-µL duplexed PCR probe assay was composed of 1X qScript XLT 1-Step RT-qPCR ToughMix (QuantaBio), 0.1 U/µL SpeedSTAR HS DNA polymerase (Takara Bio), 0.1 U/µL AccuStart II Taq DNA 314 315 polymerase (QuantaBio), 1 mg/mL BSA (New England Biolabs), 0.1 % Tween-20 (Sigma Aldrich) and 316 primer-probe pairs. For duplexed assay for N1 and control RNA, the assay contains 1 µM each N1 primer, 317 0.45 µM each Luciferase primer, 1 µM N1 probe and 0.25 µM Luciferase probe. For duplexed assay for influenza A and influenza B, the assay contains 0.5 μM each influenza A primer, 1 μM each influenza B 318 319 primer, 0.25 µM influenza A probe and 0.5 µM influenza B probe. For duplexed assay of SARS-CoV-2 320 variant detection, the assay contains 0.67 μ M each Yale Spike Δ 69-70 primer, 0.3 μ M each Yale ORF1a 321 Δ 3675-3677 primer, 0.2 μ M Yale Spike Δ 69-70 probe and 0.2 μ M ORF1a Δ 3675-3677 probe. All oligonucleotides, including primers and fluorescently labeled DNA probe (sequences in Supplementary 322 323 Table 4) were purchased from Integrated DNA Technologies.

324 Cartridge fabrication and assembly

The magnetofluidic cartridges were assembled from three thermoplastic layers (Supplementary Fig. 2). The bottom layer was fabricated by thermoforming 10 mil (~0.25 mm) thick polyethylene terephthalate glycol (PETG) sheet (Welch Fluorocarbon) over 3D-printed molds (Form 2, Formlabs) designed in Fusion 360 (Autodesk) to produce extruded wells. The middle layer was laser-cut from 0.75 mm thick acrylic (ePlastics) with pressure-sensitive adhesive (PSA) (9472LE adhesive transfer tape, 3M) laminated on both sides. The top layer was laser-cut from 1.5 mm thick clear acrylic sheet (McMaster-Carr, USA) with Teflon tape (McMaster-Carr) laminated to one side and patterned by laser-etching.

332 To load reagents into the cartridge wells, the thermoformed section and acrylic middle layer were 333 first joined with PSA, followed by dispensing 7.5 µL PCR solution and 50 µL wash buffer (W14, 334 ChargeSwitch Total RNA Cell Kit, Invitrogen) into corresponding wells. With aqueous reagents pre-loaded, 335 the cartridge was sealed by lamination with the top layer using the PSA on the other side of the middle 336 layer. Once sealed, 420 µL silicone oil (100 cSt, Millipore-Sigma) was injected through the sample injection 337 port to cover the wells and fill the remaining space within the cartridge except for the first well. To create 338 the wax plug in the first well, 40 µL of molten docosane wax (Millipore-Sigma) was dispensed into the 339 sample port and melted into the oil with a custom heating rig followed by cooling at room temperature 340 to solidify. The cartridge was either used immediately or the sample injection port was sealed with 341 adhesive tape (Scotch Magic Tape, 3M) and the cartridge stored on ice or frozen until use.

342 Instrument design

Laser-cut and 3D-printed housing and fixtures of the instrument was designed in Fusion 360. 343 344 External walls were laser-cut from 1/8" thick acrylic (McMaster-Carr) and 3D-printed components were fabricated using an SLA (Form 2, Black Resin, Formlabs) or FDM printer (Prusa Mini, Prusament PETG, 345 346 Prusa research). A 5-inch HDMI touchscreen (Elecrow) was mounted on top of the instrument to allow 347 user input with the graphic user interface (GUI) designed in python using the Tkinter library. Motorized 348 actuation of an arm containing opposing neodymium magnets (K&J Magnetics) was implemented with a 349 micro servo motor (TowerPro SG51R) mounted on a carriage guided along two aluminum rails by a second 350 servo motor (Hitec HS-485HB). A third servo motor (Hitec HS-485HB) pivoted an aluminum rod to swivel 351 the heat blocks onto the cartridge. The sample well heat block was custom machined out of 6061 352 aluminum and mounted onto a power resistor (Riedon PF1262-5RF1) with a steel M3 screw, while the PCR heat block was machined from 145 copper and mounted onto a thermoelectric element (Peltier Mini 353 354 Module, Custom Thermoelectric) and heatsink using thermally conductive epoxy (Arctic Alumina Thermal 355 Adhesive, Arctic Silver). Temperature of the heat blocks was monitored with a thermistor probe 356 (GA100K6MCD1, TE Connectivity) epoxied directly adjacent to the wells. A 5V fan (Sunon) provided 357 cooling to the heatsink.

358 Cartridges were illuminated using the red and blue channels of a 3-color RGB LED (Vollong) passed 359 through a focusing lens (10356, Carclo) and dual bandpass excitation filter (59003m, Chroma). 360 Fluorescence was captured with a CMOS camera (Pi NoIR Camera V2, Raspberry Pi) through a dual 361 bandpass emission filter (535-700DBEM, Omega Optical). An Arduino Nano microcontroller coordinated 362 control of the LEDs, fan, and motors, and a Raspberry Pi 3B+ ran the GUI, processed fluorescence images, 363 monitored thermistor readings and provided current to the heat blocks via a motorshield (Dual TB9051FTG Motor Driver, Pololu). Power to the instrument was supplied with a 7.5V 45W wall adapter 364 365 (MEAN WELL GST60A07-P1J).

366 Cartridge limit of detection determination

367 Limit of detection of the cartridge assays was determined using contrived specimens of viral 368 particles spiked into nasopharyngeal swab or saliva samples. Gamma-irradiated viral particles from SARS-369 Related Coronavirus 2 (Isolate USA-WA1/2020), Influenza A/Puerto Rico/8/1934-9VMC2(NR-29027), and 370 Influenza B virus B/Nevada/03/2011 (BV) (NR-44023) were obtained through the BEI Resources 371 Repository and stored at -80 °C upon receipt. To prepare the contrived samples, a serial dilution of viral 372 particles were spiked into pooled (n = 4) clinical specimens (confirmed PCR-negative by the Johns Hopkins 373 Clinical Microbiology Lab). Each concentration was tested a minimum of three times, and the limit of 374 detection was determined when one of the replicates showed negative. Fifty microliters of swab eluate 375 or five microliters of saliva was first mixed with 150 µL magnetic bead binding buffer consisting of 0.67 mg/mL ChargeSwitch beads, 0.5M KCl in 100mM aqueous MES, and 10⁵ copies of Luciferase RNA internal 376 377 control (Promega). The entire mixture of sample and bead buffer was loaded into the sample port of the 378 cartridge followed by insertion into the instrument for processing.

379 Clinical sample testing

380 Clinical swab and saliva specimens were previously collected under Johns Hopkins IRB #00246027. Specimens were de-identified and blinded before testing. Nasopharyngeal swabs were eluted in 3 mL of 381 382 Universal Transport Medium. Passive drooled saliva specimens were collected into an empty vessel. Five 383 microliters of saliva was lysed with 50 µL of aqueous buffer containing 1% Triton X-100 and 1.2 units of 384 Thermolabile Proteinase K (P8111S, New England Biolabs). 50 μL of swab eluate or 55 μL of saliva with 385 lysis buffer was mixed with 150 µL magnetic bead binding buffer as previously described followed by loading the entire mixture into the sample port of the cartridge. The comparator assay for evaluation of 386 clinical samples used a modified CDC testing protocol³² for swabs (Supplementary Methods, 387 Supplementary Fig. 8) and FDA EUA authorized SalivaDirect protocol⁴³ for saliva were employed to test all 388 389 the clinical specimens on a Bio-Rad CFX96 Touch Real-Time PCR System as reference.

390 Testing of SARS-CoV-2 variants used RNA from clinical samples extracted using a chemagic 360 391 instrument (PerkinElmer) with clades of each sample previously characterized by sequencing³¹. 2 μ L of 392 extracted RNA was mixed with 150 μ L magnetic bead binding buffer following by loading into the sample 393 port of the cartridge.

394 Acknowledgements

We thank Emily Chang for her help with the instrument's graphical user interface, and Shawna Lewis and Chun Huai (Alex) Luo for their assistance in collecting and preparing clinical samples. This work was supported by funding through the National Institutes of Health (R01Al138978, R01Al137272, R61Al154628).

399 Competing Interests

400 AYT and T-HW are coinventors on patent PCT/US2019/029937 "A Disposable Reagent Scaffold for 401 Biochemical Process Integration".

- 402 Supplementary Materials
- 403 Supplementary Methods

404	Supp	ementary	Figures List
-----	------	----------	---------------------

- 405 Fig. S1. Loading Cartridges and Instrument Operation
- 406 Fig. S2. Cartridge Assembly
- 407 Fig. S3. Nucleic Acid Aliquoting with Sequential Elution
- 408 **Fig. S4.** Servo actuation for cartridge mounting and magnetic transfer
- 409 Fig. S5. Heat block simulation and design for rapid thermocycling
- 410 Fig. S6. Fluorescence processing algorithm
- 411 Fig. S7. Detection of SARS-CoV-2 in saliva
- 412 Fig. S8. Comparator assay evaluation
- 413
- 414 Supplementary Tables List
- 415 **Table 1.** Instrument bill of materials
- 416 **Table 2.** Specificity testing
- 417 Table 3. Clinical samples data
- 418 **Table 4.** PCR primers and probes
- 419
- 420 Supplementary Movies
- 421 Movie S1. On-cartridge sample processing
- 422

423 References

- Sutton, D., Fuchs, K., D'Alton, M. & Goffman, D. Universal Screening for SARS-CoV-2 in Women
 Admitted for Delivery. *N. Engl. J. Med.* 382, 2163–2164 (2020).
- Kucharski, A. J. *et al.* Effectiveness of isolation, testing, contact tracing, and physical distancing on
 reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study.
 Lancet Infect. Dis. 20, 1151–1160 (2020).
- 429 3. Peto, J. *et al.* Weekly COVID-19 testing with household quarantine and contact tracing is feasible
 430 and would probably end the epidemic: Weekly Covid-19 testing. *R. Soc. Open Sci.* 7, 0–3 (2020).
- 431 4. Galloway, S. E. *et al.* Emergence of SARS-CoV-2 B.1.1.7 Lineage United States, December 29,
 432 2020–January 12, 2021. *MMWR. Morb. Mortal. Wkly. Rep.* **70**, 95–99 (2021).
- 4335.Volz, E. *et al.* Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking434epidemiological and genetic data. *medRxiv* 2020.12.30.20249034 (2021).

- 435 6. Lauring, A. S. & Hodcroft, E. B. Genetic Variants of SARS-CoV-2 What Do They Mean? JAMA J.
 436 Am. Med. Assoc. 325, 529–531 (2021).
- Grubaugh, N. D., Hodcroft, E. B., Fauver, J. R., Phelan, A. L. & Cevik, M. Public health actions to
 control new SARS-CoV-2 variants. *Cell* 184, 1127–1132 (2021).
- 439 8. Veldhoen, M. & Simas, J. P. Endemic SARS-CoV-2 will maintain post-pandemic immunity. *Nat.*440 *Rev. Immunol.* (2021). doi:10.1038/s41577-020-00493-9
- 441 9. Gwinn, M., MacCannell, D. & Armstrong, G. L. Next-Generation Sequencing of Infectious
 442 Pathogens. *JAMA* **321**, 893 (2019).
- 443 10. Vogels, C. B. *et al.* PCR assay to enhance global surveillance for SARS-CoV-2 variants of concern.
 444 *medRxiv* 351, 2021.01.28.21250486 (2021).
- 445 11. Babiker, A., Myers, C. W., Hill, C. E. & Guarner, J. SARS-CoV-2 Testing. *Am. J. Clin. Pathol.* 153, 706–708 (2020).
- WHO. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases.
 Interim guidance. (2020). Available at: https://www.who.int/publications/i/item/10665-331501.
 (Accessed: 6th December 2020)
- McGarry, B. E., SteelFisher, G. K., Grabowski, D. C. & Barnett, M. L. COVID-19 Test Result
 Turnaround Time for Residents and Staff in US Nursing Homes. *JAMA Intern. Med.* 181, 556
 (2021).
- 453 14. Peeling, R. W. *et al.* Serology testing in the COVID-19 pandemic response. *Lancet Infect. Dis.* 20, e245–e249 (2020).
- 455 15. Foundation for Innovative New Diagnostics (FIND). FIND evaluation update: SARS-CoV-2 Assays.
 456 Available at: https://www.finddx.org/covid-19/sarscov2-eval/. (Accessed: 6th December 2020)
- 457 16. Weissleder, R., Lee, H., Ko, J. & Pittet, M. J. COVID-19 diagnostics in context. *Sci. Transl. Med.* 12, 1–7 (2020).
- 459 17. Pipper, J. *et al.* Catching bird flu in a droplet. *Nat. Med.* **13**, 1259–1263 (2007).
- 460 18. Shin, D. J. & Wang, T. H. Magnetic Droplet Manipulation Platforms for Nucleic Acid Detection at
 461 the Point of Care. *Ann. Biomed. Eng.* 42, 2289–2302 (2014).
- 462 19. Zhang, Y. & Nguyen, N.-T. Magnetic digital microfluidics a review. *Lab Chip* 17, 994–1008
 463 (2017).
- 464 20. Egatz-Gómez, A. et al. Discrete magnetic microfluidics. Appl. Phys. Lett. 89, (2006).
- Shin, D. J. *et al.* Mobile nucleic acid amplification testing (mobiNAAT) for Chlamydia trachomatis
 screening in hospital emergency department settings. *Sci. Rep.* **7**, 4495 (2017).
- Shin, D. J., Trick, A. Y., Hsieh, Y. H., Thomas, D. L. & Wang, T. H. Sample-to-Answer Droplet
 Magnetofluidic Platform for Point-of-Care Hepatitis C Viral Load Quantitation. *Sci. Rep.* 8, (2018).
- Trick, A. Y. *et al.* A portable magnetofluidic platform for detecting sexually transmitted infections
 and antimicrobial susceptibility. *Sci. Transl. Med.* 13, (2021).
- 471 24. Goldenberger, D. et al. Brief validation of the novel GeneXpert Xpress SARS-CoV-2 PCR assay. J.

472		Virol. Methods 284 , 113925 (2020).
473 474	25.	Liotti, F. M. <i>et al.</i> Evaluating the newly developed BioFire COVID-19 test for SARS-CoV-2 molecular detection. <i>Clin. Microbiol. Infect.</i> 26 , 1699–1700 (2020).
475 476 477	26.	Johnson, D. R., Lee, P. K. H., Holmes, V. F. & Alvarez-Cohen, L. An internal reference technique for accurately quantifying specific mRNAs by real-time PCR with application to the tceA reductive dehalogenase gene. <i>Appl. Environ. Microbiol.</i> 71 , 3866–3871 (2005).
478 479	27.	Lu, X. <i>et al.</i> US CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome Coronavirus 2. <i>Emerg. Infect. Dis.</i> 26 , 1654–1665 (2020).
480 481 482	28.	Van Elden, L. J. R., Nijhuis, M., Schipper, P., Schuurman, R. & Van Loon, A. M. Simultaneous detection of influenza viruses A and B using real-time quantitative PCR. <i>J. Clin. Microbiol.</i> 39 , 196–200 (2001).
483 484 485	29.	Terrier, O. <i>et al.</i> Cellular transcriptional profiling in human lung epithelial cells infected by different subtypes of influenza A viruses reveals an overall down-regulation of the host p53 pathway. <i>Virol. J.</i> 8 , 285 (2011).
486 487 488 489	30.	World Health Organization. WHO information for the molecular detection of influenza viruses. (2020). Available at: https://www.who.int/influenza/gisrs_laboratory/Protocols_influenza_virus_detection_Jan_2020. pdf. (Accessed: 27th February 2021)
490 491	31.	Thielen, P. M. <i>et al.</i> Genomic diversity of SARS-CoV-2 during early introduction into the Baltimore-Washington metropolitan area. <i>JCI Insight</i> 6 , (2021).
492 493	32.	Centers for Disease Control and Prevention (CDC). CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel, Revision: 06. (2020).
494 495	33.	Peto, J., Hunter, D. J., Riboli, E. & Griffin, J. L. Unnecessary obstacles to COVID-19 mass testing. Lancet 396 , 1633 (2020).
496 497 498	34.	Woo, C. H., Jang, S., Shin, G., Jung, G. Y. & Lee, J. W. Sensitive fluorescence detection of SARS-CoV-2 RNA in clinical samples via one-pot isothermal ligation and transcription. <i>Nat. Biomed. Eng.</i> 4 , 1168–1179 (2020).
499 500	35.	Dao Thi, V. L. <i>et al.</i> A colorimetric RT-LAMP assay and LAMP-sequencing for detecting SARS-CoV-2 RNA in clinical samples. <i>Sci. Transl. Med.</i> 12 , (2020).
501 502	36.	Ganguli, A. <i>et al.</i> Rapid isothermal amplification and portable detection system for SARS-CoV-2. <i>Proc. Natl. Acad. Sci.</i> 117 , 22727–22735 (2020).
503 504 505	37.	Behrmann, O. <i>et al.</i> Rapid Detection of SARS-CoV-2 by Low Volume Real-Time Single Tube Reverse Transcription Recombinase Polymerase Amplification Using an Exo Probe with an Internally Linked Quencher (Exo-IQ). <i>Clin. Chem.</i> 66 , 1047–1054 (2020).
506 507	38.	Broughton, J. P. <i>et al.</i> CRISPR–Cas12-based detection of SARS-CoV-2. <i>Nat. Biotechnol.</i> 38 , 870– 874 (2020).
508 509	39.	Gootenberg, J. S. <i>et al.</i> Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a and Csm6. <i>Science (80).</i> 360 , 439–444 (2018).

- 510 40. Xu, G. *et al.* Paper-Origami-Based Multiplexed Malaria Diagnostics from Whole Blood. *Angew.*511 *Chemie* **128**, 15476–15479 (2016).
- 512 41. Daher, R. K., Stewart, G., Boissinot, M. & Bergeron, M. G. Recombinase polymerase amplification 513 for diagnostic applications. *Clin. Chem.* **62**, 947–958 (2016).
- 42. Pradhan, R., Weber, L. & Recht, H. Lack of Antigen Test Reporting Leaves Country 'Blind to the
 Pandemic'. *Kaiser Health News* (2020). Available at: https://khn.org/news/lack-of-antigen-testreporting-leaves-country-blind-to-the-pandemic/. (Accessed: 21st April 2021)
- 51743.FDA. Yale School of Public Health, Department of Epidemiology of Microbial Diseases SalivaDirect518assay EUA Summary Updated April 9, 2021. Available at:
- 519 https://www.fda.gov/media/141192/download. (Accessed: 21st April 2021)